News

Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion

LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a…

2 years ago

Revolutionizing Regtech: LighthouseAI Secures Strategic Investment and Landmark Law Firm Partnership

LighthouseAI Set to Impact the Regulatory Technology Industry with AI-driven ComplianceLOS ANGELES, CA / ACCESSWIRE / November 16, 2023 /…

2 years ago

REMORY, a Supplement Known for Containing Plasmalogens, Which Are Recognized for Their Role in Preventing Cognitive Decline, Now Available in the United States

REMORY: Elevate Cognitive Health with Unique Sea Squirt-Derived Plasmalogens. Now in the U.S., this Japanese-Innovated Supplement Combines EPA, DHA, and…

2 years ago

Laxxon Medical joins German Accelerator’s Southeast Asia Market Access Class of 2023, marking the Company’s inaugural globalization venture

NEW YORK, NY / ACCESSWIRE / November 16, 2023 / Pharmaceutical 3D screen printing company Laxxon Medical has been selected…

2 years ago

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS has executed a non-binding term sheet for licensing of NLS intellectual propertyNLS has secured an additional bridge loan through…

2 years ago

Harbour Coca Approved to Commercially Distribute Coca Leaf Internationally Following Landmark Trade Agreement with Peruvian State-Run Coca Leaf Producer

Harbour Becomes Authorized Agent of Coca Globally, Permitting the Distribution of Ethically Sourced, High-Quality Coca Leaf For Emerging OpportunitiesToronto, Ontario--(Newsfile…

2 years ago

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…

2 years ago

Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS

POLB 001 - a potential blockbuster immunomodulatorLONDON, UK / ACCESSWIRE / November 16, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or…

2 years ago

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…

2 years ago